| 750 Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention.
749 Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
748 Integrated genomic and molecular characterization of cervical cancer.
747 Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.
746 Genetic dissection of colorectal cancer progression by orthotopic transplantation of engineered cancer organoids.
745 Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells.
744 Multiepitope tissue analysis reveals SPPL3-mediated ADAM10 activation as a key step in the transformation of melanocytes.
743 High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients.
742 Profiling of melanoma patients treated with checkpoint blockade reveals TCR clonality and copy number loss as correlates of therapeutic response.
741 The epidermal polarity protein Par3 is a non–cell autonomous suppressor of malignant melanoma.
740 CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia.
739 AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy.
738 IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting.
737 A genome-wide association study yields five novel thyroid cancer risk loci.
736 Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.
735 Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation.
734 Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin.
733 Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.
732 Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer.
731 Systemic Immunity Is Required for Effective Cancer Immunotherapy.